Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥6,193 JPY
Change Today +36.00 / 0.58%
Volume 2.7M
As of 2:00 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for takeda pharmaceutical co ltd (4502)

Year over year, Takeda Pharmaceutical Company Limited has seen their bottom line shrink from ¥131.2B JPY to ¥106.7B JPY despite an increase in revenues from ¥1.6T JPY to ¥1.7T JPY. An increase in the percentage of sales devoted to income tax expenses from -0.25% to 2.91% was a key component in the falling bottom line in the face of rising revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of Japanese Yens
As of:Mar 31
Mar 31
Mar 31
Mar 31
4 Year
TOTAL REVENUES1,419,385.01,508,932.01,557,267.01,691,685.0
Cost of Goods Sold317,582.0433,194.0447,628.0490,263.0
GROSS PROFIT1,101,803.01,075,738.01,109,639.01,201,422.0
Selling General & Admin Expenses, Total734,719.0810,711.0987,134.0556,210.0
R&D Expenses------341,560.0
Depreciation & Amortization, Total------143,202.0
Other Operating Expenses------27,048.0
OTHER OPERATING EXPENSES, TOTAL734,719.0810,711.0987,134.01,068,020.0
OPERATING INCOME367,084.0265,027.0122,505.0133,402.0
Interest Expense-1,335.0-1,883.0-3,323.0-4,888.0
Interest and Investment Income6,191.06,296.05,192.04,689.0
NET INTEREST EXPENSE4,856.04,413.01,869.0-199.0
Income (Loss) on Equity Investments451.0302.0866.01,000.0
Currency Exchange Gains (Loss)---2,382.0613.0-11,750.0
Other Non-Operating Income (Expenses)-819.03,245.0-12,685.0-13,941.0
EBT, EXCLUDING UNUSUAL ITEMS371,572.0270,605.0113,168.0108,512.0
Gain (Loss) on Sale of Investments----53,071.039,658.0
Gain (Loss) on Sale of Assets--17,596.04,026.06,577.0
Other Unusual Items, Total---35,723.0-40,558.04,103.0
Other Unusual Items---35,489.03,090.0--
EBT, INCLUDING UNUSUAL ITEMS371,572.0252,478.0129,707.0158,850.0
Income Tax Expense121,325.0125,207.0-3,880.049,292.0
Minority Interest in Earnings-2,379.0-3,109.0-2,343.0-2,900.0
Earnings from Continuing Operations250,247.0127,271.0133,587.0109,558.0
NET INCOME247,868.0124,162.0131,244.0106,658.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS247,868.0124,162.0131,244.0106,658.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS247,868.0124,162.0131,244.0106,658.0

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,193.00 JPY +36.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.85 USD -0.15
Baxter International Inc $69.65 USD -0.29
Becton Dickinson and Co $142.00 USD -1.94
Biogen Inc $385.80 USD -0.42
Merck KGaA €96.32 EUR -3.22
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings 64.5x
Price/Sales 2.8x
Price/Book 1.9x
Price/Cash Flow 14.1x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at